October 17, 2023: During the NITAG meeting, the discussion centered on the implementation of a vaccine specifically adapted to sub-lineages XBB (derived from Omicron) of SARS-CoV-2. The resolution, supported unanimously, recommends the administration of this adapted vaccine to defined high-risk groups. These include individuals aged 70 and older, those over 50 with comorbidities associated with a higher risk of severe COVID-19, individuals with moderate to severe immunosuppression, pregnant women, individuals with Down syndrome, and healthcare personnel directly involved in patient care. Additionally, the resolution proposes that booster doses for these groups be administered at least 6 months after their last dose, regardless of previous vaccination history or infection status. For individuals previously unvaccinated, the recommendation varies: a single dose is suggested for those under 50, while those over 50 with moderate to severe immunosuppression or recipients of hematopoietic stem cells are advised to receive three doses. This comprehensive approach aims to mitigate the impact of COVID-19 and protect vulnerable populations in Uruguay.